相关实验视频
Updated: Jan 22, 2026

07:54
A Method to Assess Bacteriocin Effects on the Gut Microbiota of Mice
Published on: July 25, 2017
14.7K
肠肺轴:肠道微生物群对肺部疾病的影响和机制
Jiaxin Liu1, Weichen Hong1, Zhendong Sun1
1College of Animal Science and Technology, Northeast Agricultural University, Harbin, China.
Frontiers in immunology
|January 21, 2026
概括
肠道微生物群通过肠肺轴影响肺部健康. 微生物代谢物如SCFA,托代谢物和多氨酸调节免疫反应,而失生症可以加剧肺炎,这表明基于微生物的疗法.
科学领域:
- 微生物组研究的研究.
- 免疫学 免疫学 免疫学
- 呼吸系统药物 呼吸系统药物
背景情况:
- 肠肺轴将肠道微生物群与呼吸系统疾病联系起来.
- 肠道疾病与喘,COPD,ARDS和肺纤维化有关.
- 肺部肠道微生物免疫调节的机制尚未完全理解.
研究的目的:
- 系统地审查肠道微生物及其代谢物如何调节肺免疫.
- 阐明肠道失生症加剧肺炎的机制.
- 探索针对呼吸道疾病的基于微生物组的干预措施.
主要方法:
- 对肠道微生物代谢产物 (SCFA,托代谢产物,PA) 的实验和临床证据的审查.
- 分析肠肺轴中的跨器官通讯通路.
- 评估益生菌,FMT和CRISPR-Cas系统的治疗潜力.
主要成果:
- 肠道微生物代谢物 (SCFA,酸代谢物,PA) 在免疫调节和屏障功能中起着关键作用.
- 肠道功能失调会破坏这些代谢物,通过肠肺轴加剧肺炎.
- 益生菌,FMT和CRISPR-Cas显示出恢复肠道平衡和治疗肺部疾病的希望.
结论:
- 肠道微生物群通过肠肺轴显著影响呼吸系统健康.
- 准肠道微生物代谢物为肺部疾病提供了一种新的治疗策略.
- 对非侵入性采样和个性化微生物组疗法的进一步研究至关重要.
相关概念视频
Physiology of Enteric Nervous System and Gut Health
898
The gastrointestinal tract, responsible for the digestion and absorption of nutrients, is safeguarded by the intestinal barrier, which consists of secretory, physical, and immune components. At the forefront is the secretory barrier, composed of essential elements such as mucus, gut microbiota, and defense proteins. They collaborate to break down food particles, facilitate nutrient absorption, and maintain optimal gut health. These secretory components ensure the smooth functioning of the...
898
Chronic Obstructive Pulmonary Disease
2.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.3K
Lung Capacity
56.1K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.1K
Chronic Obstructive Pulmonary Disease-I: Introduction
3.6K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.6K
Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.3K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.3K

